Search Result

Results for "

p38α inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Autophagy (23) Casein Kinase (4) Drug Isomer (1) Epigenetic Reader Domain (1) ERK (1) Isotope-Labeled Compounds (1) JAK (1) JNK (2) MAP3K (1) MAPKAPK2 (MK2) (2) Organoid (2) p38 MAPK (64) PROTACs (1) Raf (1) Reactive Oxygen Species (1) Src (5) Syk (1) TGF-β Receptor (4) Tie (1) TNF Receptor (2) VEGFR (1)
By Research Areas:	Cancer (27) Cardiovascular Disease (4) Inflammation/Immunology (51) Metabolic Disease (2) Neurological Disease (7)
Click Chemistry:	Alkynes (2)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-114423

p38α inhibitor 1	p38 MAPK Autophagy	Inflammation/Immunology
p38α inhibitor 1 is a *p38α* inhibitor extracted from patent WO 2008076265 A1.

HY-153002

p38α inhibitor 3	p38 MAPK	Inflammation/Immunology
p38α inhibitor 3 (Comp G7) is a *p38α* inhibitor that blocks the effectiveness of myoblast differentiation .

HY-131335

p38α inhibitor 2	p38 MAPK	Inflammation/Immunology
p38α inhibitor 2 is a highly potent and selective p38α MAPK inhibitor, with a pIC₅₀ of 9.6. p38α inhibitor 2 inhibits the hERG ion channel (IC₅₀=27 μM) and shows a promising selectivity profile when tested in a panel of 51 other protein kinases (<30% inhibition at 10 μM concentration) and a panel of 141 other biological targets .

HY-159799

p38α inhibitor 5	p38 MAPK	Cancer
p38α inhibitor 5 (compound 1) is a PROTAC-type target protein ligand targeting p38 and can be used to synthesize NR-11c (HY-159798) .

HY-18874

p38-α MAPK-IN-1 1 Publications Verification	p38 MAPK Autophagy	Others
p38-α MAPK-IN-1 is an inhibitor of MAPK14 (p38-α), with IC₅₀ of 2300 nM in EFC displacement assay, and 5500 nM in HTRF assay .

HY-14412

p38α inhibitor 4	p38 MAPK	Cancer
p38α inhibitor 4 (compound 10) is a selective and allosteric *p38α* inhibitor with an IC₅₀ value of 1.2 μM. p38α inhibitor 4 exhibits no activity against p38β, p38γ, and p38δ .

HY-161293

p38-α MAPK-IN-6	p38 MAPK	Cancer
p38-α MAPK-IN-6 (compound 3a) is a *p38α* mitogen-activated protein kinase inhibitor .

HY-146032

p38-α MAPK-IN-4	p38 MAPK	Neurological Disease Inflammation/Immunology
p38-α MAPK-IN-4 (Compound 69) is a selective p38α MAPK inhibitor with an IC₅₀ of 1.5 µM. p38-α MAPK-IN-4 rapidly and strongly prevents the development of mechanical allodynia (MA) in vivo .

HY-162364

p38-α MAPK-IN-7	p38 MAPK	Neurological Disease
p38-α MAPK-IN-7 (compound 4) is a *p38α-MAPK* inhibitor with an IC₅₀ value of 98.7 nM. p38-α MAPK-IN-7 protects neuronal cells from dexamethasone-induced ROS production .

HY-147518

p38-α MAPK-IN-5	p38 MAPK	Inflammation/Immunology
p38-α MAPK-IN-5 (compound 4e) is a potent *p38α* inhibitor with IC₅₀s of 0.1 nM, 0.2 nM, 944 nM, 4100 nM for p38α, p38 β, p38γ, p38δ, respectively. p38-α MAPK-IN-5 has anti-inflammatory effect. p38-α MAPK-IN-5 has the potential for asthma and chronic obstructive pulmonary disease (COPD) research .

HY-161462

ERK2/p38α MAPK-IN-1	ERK p38 MAPK	Cancer
ERK2/p38α MAPK-IN-1 (Compound 1, In silico Hit-2) is a potent and selective ERK2 and p38α MAPK inhibitor, with an IC₅₀ of 82 μM for ERK2. ERK2/p38α MAPK-IN-1 binds to the allosteric site of ERK2 and p38α MAPK in distinct manners. ERK2/p38α MAPK-IN-1 can be used for the research of type 2 diabetes .

HY-14975

R1487 Hydrochloride 1 Publications Verification	p38 MAPK Autophagy	Cancer
R1487 Hydrochloride is a highly potent and selective *p38α* inhibitor, with K_d values of 0.2 nM and 29 nM for p38α and p38β, respectively .

HY-10401

VX-702 3 Publications Verification	p38 MAPK Autophagy	Inflammation/Immunology
VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β .

HY-168841

p38α-MK2-IN-1	MAPKAPK2 (MK2) p38 MAPK	Inflammation/Immunology
p38α-MK2-IN-1 (Compound 36) is a *p38α-MK2* complex inhibitor (IC₅₀: 5 nM). p38α-MK2-IN-1 has a robust inflammation inhibitory effect and joint repair ability .

HY-11087

SD 0006 SD-06	p38 MAPK Autophagy	Inflammation/Immunology
SD 0006 (SD-06) is an orally active, selective, ATP-competitive and potent diaryl pyrazole inhibitor of p38α MAP kinase, with an IC₅₀ of 110 nM for p38α .

HY-108645

AL 8697	p38 MAPK Autophagy	Inflammation/Immunology
AL 8697 is a specific and orally active p38α MAPK inhibitor with an IC₅₀ of 6 nM. AL 8697 displays 14-fold greater inhibition of p38α compared to p38β (IC₅₀=82 nM), and 300-fold selectivity for p38α over a panel of 91 kinases. Anti-inflammatory activity .

HY-112401

p38 MAP Kinase Inhibitor IV	p38 MAPK	Inflammation/Immunology
p38 MAP Kinase Inhibitor IV is a highly specific ATP-competitive p38α MAPK inhibitor with IC₅₀s of 0.13 and 0.55 μM for p38α and p38β MAPK, respectively .

HY-10328

Neflamapimod 5+ Cited Publications VX-745	p38 MAPK Autophagy	Inflammation/Immunology
Neflamapimod (VX-745) is a potent, blood-brain barrier penetrant, highly selective inhibitor of *p38α* inhibitor with an IC₅₀ for p38α of 10 nM and for p38β of 220 nM. Neflamapimod (VX-745) possesses anti-inflammatory activity.

HY-105997

AZD 6703	Others	Others
AZD 6703 is a p38α MAP kinase inhibitor with activity in inflammatory diseases.

HY-14305

BMS-582949	p38 MAPK	Inflammation/Immunology
BMS-582949 (compound 7k) is an orally active and highly selective p38α MAP kinase inhibitor, with IC₅₀ values of 13 nM for *p38α*, and 50 nM for cellular TNFα. BMS-582949 can be used for research on rheumatoid arthritis .

HY-10403

PH-797804 5+ Cited Publications	p38 MAPK Autophagy	Inflammation/Immunology Cancer
PH-797804 is a ATP-competitive, selective *p38α/p38β* inhibitor (IC₅₀=26 nM and K_i=5.8 nM for p38α; K_i=40 nM for p38β) and does not inhibit JNK2.

HY-120111

MW-150 MW01-18-150SRM	p38 MAPK Autophagy	Neurological Disease Inflammation/Immunology
MW150 (MW01-18-150SRM) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a K_i of 101 nM. MW-150 inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia .

HY-120823

PF-05381941	MAP3K p38 MAPK	Inflammation/Immunology
PF-05381941 is a potent dual inhibitor of *TAK1/p38α, with IC₅₀*s of 156 and186 nM, respectively .

HY-N8251

Cyclocurcumin	p38 MAPK	Cardiovascular Disease Inflammation/Immunology
Cyclocurcumin is a potent *p38α* inhibitor. Cyclocurcumin shows antirheumatic, antivasoconstrictive and antioxidant activities .

HY-159798

NR-11c	PROTACs p38 MAPK	Cancer
NR-11c is a selective and potent p38α PROTAC degrader. NR-11c effectively degrades *p38α* in a variety of tumor cells. When administered intraperitoneally or intravenously to mice, NR-11c primarily acts in the liver. NR-11c can be used in cancer research. (Pink: p38α inhibitor 5 (HY-159799); Black: linker (HY-159800); Blue: VHL E3 ligase ligand (HY-112078)) .

HY-151921

Anti-inflammatory agent 33	p38 MAPK	Inflammation/Immunology
Anti-inflammatory agent 33 is a potent *p38α* inhibitor. Anti-inflammatory agent 33 inhibits NO production. Anti-inflammatory agent 33 inhibits LPS-induced iNOS, COX-2, p-p38α, p-MK2 protein expression. Anti-inflammatory agent 33 shows anti-inflammatory activity .

HY-120111A

MW-150 hydrochloride MW01-18-150SRM hydrochloride	p38 MAPK Autophagy	Neurological Disease Inflammation/Immunology
MW-150 hydrochloride (MW01-18-150SRM hydrochloride) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a K_i of 101 nM. MW-150 hydrochloride (MW01-18-150SRM hydrochloride) inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia .

HY-16715

Acumapimod 1 Publications Verification BCT197	p38 MAPK Autophagy	Inflammation/Immunology
Acumapimod (BCT197) is an orally active p38 MAP kinase inhibitor, with an IC₅₀ of less than 1 μM for p38α.

HY-120111B

MW-150 dihydrochloride dihydrate MW01-18-150SRM dihydrochloride dihydrate	p38 MAPK Autophagy	Neurological Disease Inflammation/Immunology
MW-150 dihydrochloride dihydrate (MW01-18-150SRM dihydrochloride dihydrate) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a K_i of 101 nM. MW-150 dihydrochloride dihydrate (MW01-18-150SRM dihydrochloride dihydrate) inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia .

HY-135674

SR-318	p38 MAPK TNF Receptor	Inflammation/Immunology Cancer
SR-318 is a potent and highly selective p38 MAPK inhibitor with IC₅₀s of 5 nM, 32 nM and 6.11 μM for p38α, p38β and p38α/β, respectively. SR-318 potently inhibits the TNF-α release in whole blood with an IC₅₀ of 283 nM. SR-318 has anti-cancer and anti-inflammatory activity .

HY-11068

SB 239063 25+ Cited Publications	p38 MAPK Autophagy	Inflammation/Immunology
SB 239063 is a potent, selective and orally active p38 MAPK inhibitor, exhibits an IC₅₀ of 44 nM for recombinant purified human p38α, with equipotent inhibitory activity against p38α and p38β. SB 239063 has no effect on p38γ or p38δ. With anti-asthma activity and also be used to enhance memory which is impaired due to aging or medical conditions, such as, AD .

HY-110398

5,6,7-Trimethoxyflavone Baicalein trimethyl ether	p38 MAPK	Inflammation/Immunology Cancer
5,6,7-Trimethoxyflavone is a novel p38-α MAPK inhibitor with an anti-inflammatory effect. 5,6,7-Trimethoxyflavone is isolated from several plants including Zeyhera tuberculosa, Callicarpa japonica, and Kickxia lanigera .

HY-14974

R 1487	p38 MAPK	Inflammation/Immunology
R 1487 is an orally active and highly selective **p38α mitogen-activated protein kinase inhibitor**. R 1487 can be used in the study of rheumatoid arthritis .

HY-136794

SB-284851-BT	p38 MAPK Epigenetic Reader Domain	Inflammation/Immunology Cancer
SB-284851-BT is an inhibitor of *BRD4/p38α/BRDT. SB-284851-BT inhibits* BRD4-BD1 (IC₅₀=1.7 µM), *p38α* (K_d=0.47 nM), BRDT (1) (IC₅₀=18 µM) and BRD4 (1)(IC₅₀=3.7 µM). SB-284851-BT reduces IL-8 production by inhibiting p38α, as well as inhibiting BRD4 to down-regulates c-Myc and NF-κB gene pathways in cancer. SB-284851-BT can combined with the bromine domain and extra terminal (BET) .

HY-145564A

Emprumapimod hydrochloride PF-07265803 hydrochloride	p38 MAPK	Cardiovascular Disease Inflammation/Immunology
Emprumapimod (PF-07265803) hydrochloride is an orally active and selective inhibitor of p38α MAPK. Emprumapimod hydrochloride can be used for the research of dilated cardiomyopathy and acute inflammatory pain .

HY-112182

UM-164 DAS-DFGO-II	Src p38 MAPK Autophagy	Cancer
UM-164 (DAS-DFGO-II) is a highly potent inhibitor of c-Src with a K_d of 2.7 nM. UM-164 also potently inhibits *p38α* and p38β.

HY-10402

Losmapimod 10+ Cited Publications GSK-AHAB; GW856553X; SB856553	p38 MAPK Autophagy	Inflammation/Immunology Cancer
Losmapimod (GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pK_is of 8.1 and 7.6 for p38α and p38β, respectively .

HY-12299

WH-4-023 4 Publications Verification Dual LCK/SRC inhibitor	Src	Cancer
WH-4-023 is a potent and selective dual Lck/Src inhibitor with IC₅₀ of 2 nM/6 nM for Lck and Src kinase respectively; little inhibition on p38α and KDR.

HY-144697

p38 MAPK-IN-3	p38 MAPK Apoptosis Reactive Oxygen Species	Cancer
p38 MAPK-IN-3 (Compound 2c) is a p38α MAPK inhibitor. p38 MAPK-IN-3 has antitumor activities and induces apoptosis and ROS .

HY-14305A

BMS-582949 hydrochloride 2 Publications Verification	p38 MAPK Autophagy	Inflammation/Immunology
BMS-582949 hydrochloride is an orally active and highly selective p38α MAPK inhibitor, with an IC₅₀ of 13 nM. BMS-582949 hydrochloride displays a significantly improved pharmacokinetic profile and is effective in inflammatory disease .

HY-160930

TOP1288	p38 MAPK Src Syk	Inflammation/Immunology
TOP1288 is a narrow spectrum kinase inhibitor for *P38α, Src* and Syk kinase, with IC₅₀ of 116nM, 24nM and 659nM, respectively. TOP1288 inhibits inflammatory cytokine release from inflamed biopsies and myofibroblasts .

HY-139553

Zunsemetinib ATI-450; CDD-450	MAPKAPK2 (MK2)	Inflammation/Immunology
Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases .

HY-108646

SX 011	p38 MAPK JNK	Inflammation/Immunology
SX 011 is a p38 inhibitor with IC₅₀s of 9 nM and 90 nM against p38α and p38β, respectively. SX 011 also inhibits JNK-2 with an IC₅₀ of 100 nM. SX-011 is orally bioavailable .

HY-16782

Pexmetinib 1 Publications Verification ARRY-614	Tie p38 MAPK Autophagy	Cancer
Pexmetinib is a potent Tie-2 and p38 MAPK dual inhibitor, with IC₅₀s of 1 nM, 35 nM and 26 nM for Tie-2, p38α and p38β, respectively, and can be used in the research of acute myeloid leukemia.

HY-107597

Halicin 1 Publications Verification SU3327	JNK	Metabolic Disease Inflammation/Immunology
Halicin (SU3327) is a potent, selective and substrate-competitive JNK inhibitor with an IC₅₀ of 0.7 μM. Halicin also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC₅₀ of 239 nM. Halicin shows less active against p38α and Akt kinase .

HY-W015445

SD-169	p38 MAPK	Metabolic Disease
SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, with an IC₅₀ of 3.2 nM. SD-169 also weakly inhibits p38β MAPK with an IC₅₀ of 122 nM. SD-169 prevents the development and progression of diabetes by inhibiting T cell infiltration and activation .

HY-18759

BMS-751324	p38 MAPK TNF Receptor	Inflammation/Immunology
BMS-751324 is a p38α MAPK inhibitor. BMS-751324 equips a precursor of carbamyl-methyl linkage, containing esters and phosphate functional groups derived from hydroxyphenylacetic acid (HPA). BMS-751324 effectively inhibits foot swelling and LPS-induced TNFα production in an arthritic rat model .

HY-163429

J-1149	TGF-β Receptor p38 MAPK	Inflammation/Immunology Cancer
J-1149 is a potent ALK5 inhibitor, with an IC₅₀ value of 0.017 μM. J-1149 also shows weak p38α MAP kinase inhibitory activity, with an IC₅₀ value of 0.435 μM. J-1149 can be used for liver fibrosis research .

HY-139553A

(R)-Zunsemetinib (R)-ATI-450; (R)-CDD-450	Drug Isomer	Inflammation/Immunology
(R)-Zunsemetinib is the isomer of Zunsemetinib (HY-139553), and can be used as an experimental control. Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases .

HY-151233

ALK5-IN-10	TGF-β Receptor	Cancer
ALK5-IN-10 (Compound 5d) is a TGF-β type I receptor kinase ALK5 inhibitor, with IC₅₀s of 0.007 and 1.98 μM for ALK5 and p38α, respectively. ALK5-IN-10 can be used for the research of cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N8251

Cyclocurcumin	Structural Classification Source classification Phenols Polyphenols Plants Curcuma longa Zingiberaceae	p38 MAPK
Cyclocurcumin is a potent *p38α* inhibitor. Cyclocurcumin shows antirheumatic, antivasoconstrictive and antioxidant activities .

HY-110398

5,6,7-Trimethoxyflavone Baicalein trimethyl ether	Structural Classification Flavonoids Classification of Application Fields Flavones Verbenaceae Bignoniaceae Plants Oroxylum indicum (Linn.) Bentham ex Kurz Callicarpa japonica Thunb. Inflammation/Immunology Disease Research Fields Cancer	p38 MAPK
5,6,7-Trimethoxyflavone is a novel p38-α MAPK inhibitor with an anti-inflammatory effect. 5,6,7-Trimethoxyflavone is isolated from several plants including Zeyhera tuberculosa, Callicarpa japonica, and Kickxia lanigera .

Cat. No.	Product Name	Chemical Structure

HY-10405S

Pamapimod-d4

Pamapimod-d₄ (Ro4402257-d4) is the deuterium labeled Pamapimod. Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC50s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment[1][2].

Cat. No.	Product Name		Classification

HY-159799

p38α inhibitor 5		Alkynes
p38α inhibitor 5 (compound 1) is a PROTAC-type target protein ligand targeting p38 and can be used to synthesize NR-11c (HY-159798) .

HY-125387

TOP1210		Alkynes
TOP1210 is a narrow-spectrum tyrosine kinase inhibitor with potent inhibitory activity against P38α, Src, and Syk kinases. TOP1210 effectively reduced proinflammatory cytokines released by peripheral blood monocytes, primary macrophages, HT29 cells, inflammatory cells in ulcerative colitis (UC) biopsies, and myofibroblasts isolated from inflamed colonic UC mucosa. TOP1210 showed significant anti-inflammatory effects in cell experiments and UC biopsies, superior to some selective kinase inhibitors. The multi-kinase inhibition of TOP1210 provides the possibility of obtaining a wider range of therapeutic effects, especially in the regulation of autoimmune responses .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks